Biologicals and bone loss

Therapeutic Advances in Musculoskeletal Disease

Volumn 4, Issue 4, 2012, Pages 245-247

  Krieckaert, Charlotte L m ^a   Lems, Willem F ^b  

^a Jan Van Breemen Research Institute/Reade   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ankylosing spondylitis biologicals; bone mineral density; fracture risk; osteoporosis; rheumatoid arthritis

Indexed keywords

ADALIMUMAB; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; DICKKOPF 1 PROTEIN; GLUCOCORTICOID; INFLIXIMAB; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; WNT PROTEIN;

AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS; ARTICLE; BODY MASS; BONE DENSITY; BONE EROSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG RESPONSE; FRAGILITY FRACTURE; HEALTH ASSESSMENT QUESTIONNAIRE; HIP DISEASE; HUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEX DIFFERENCE; SPINE DISEASE; TREATMENT DURATION;

EID: 84868655025     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X12441275     Document Type: Article

References (16)

1. Boyle W.J. Simonet W.S. Lacey D.L. (2003) Osteoclast differentiation and activation. Nature 15: 337–342.
2. Cortet B. Flipo R.M. Blanckaert F. Duquesnoy B. Marchandise X. Delcambre B. (1997) Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy. Rev Rhum Engl Ed 64: 451–458.
3. Cortet B. Guyot M.H. Solau E. Pigny P. Dumoulin F. Flipo R.M. et al. (2000) Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. Clin Exp Rheumatol 18: 683–690.
4. Eekman D.A. Vis M. Bultink I.E. Kuik D.J. Voskuyl A.E. Dijkmans B.A. et al. (2011) Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 70: 389–390.
5. Gough A.K. Lilley J. Eyre S. Holder R.L. Emery P. (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344: 23–27.
6. Haugeberg G. Uhlig T. Falch J.A. Halse J.I. Kvien T.K. (2000 a) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 43: 522–530.
7. Haugeberg G. Uhlig T. Falch J.A. Halse J.I. Kvien T.K. (2000 b) Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 43: 2776–2784.
8. Kang K.Y. Lee K.Y. Kwok S.K. Ju J.H. Park K.S. Hong Y.S. et al. (2011) The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis. Joint Bone Spine 78: 188–193.
9. Maillefert J.F. Aho L.S. El Maghraoui A. Dougados M. Roux C. (2001) Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 12: 605–609.
10. Ørstavik R.E. Haugeberg G. Mowinckel P. Høiseth A. Uhlig T. Falch J.A. et al. (2004) Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls. Arch Intern Med 164: 420–425.
11. Schett G. Stach C. Zwerina J. Voll R. Manger B. (2008) How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum 58: 2936–2948.
12. van Staa T.P. Geusens P. Bijlsma J.W. Leufkens H.G. Cooper C. (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54: 3104–3112.
13. Vis M. Havaardsholm E.A. Haugeberg G. Uhlig T. Voskuyl A.E. van de Stadt R.J. et al. (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65: 1495–1499.
14. Walsh N.C. Gravallese E.M. (2010) Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 233: 301–312.
15. Wheater G. Hogan V.E. Teng Y.K. Tekstra J. Lafeber F.P. Huizinga T.W. et al. (2011) Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. Osteoporos Int [Epub ahead of print].
16. Wijbrandts C.A. Klaasen R. Dijkgraaf M.G. Gerlag D.M. van Eck-Smit B.L. Tak P.P. (2009) Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 68: 373–376.